Paula Heikkilä1,2, Minna Mecklin3, Matti Korppi3. 1. Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland. paula.heikkila@uta.fi. 2. Department of Pediatrics, Tampere University Hospital, PO BOX 2000, 33521, Tampere, Finland. paula.heikkila@uta.fi. 3. Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland.
Abstract
BACKGROUND: This study evaluated the cost-effectiveness of hypertonic saline (HS) inhalations for infant bronchiolitis, compared to normal saline inhalations or standard treatment without inhalations as controls. METHODS: The decision tree in the decision analysis was used to calculate the expected costs. Actual cost data were obtained from our retrospective case-control study on bronchiolitis treatment. The effectiveness of treatment, based on the hospitalization rate of those admitted to the emergency department and the length of stay (LOS) of those who were hospitalized, was collected from previous studies. For the effectiveness estimations, we made a meta-analysis summarizing the results of the meta-analysis of the Cochrane review in 2013 and the results of 10 studies published after it. RESULTS: The mean hospitalization rate was 24.7% in the HS inhalation group and 32.6% in the control group [risk ratio: 0.80, 95% confidence interval (CI) 0.67-0.96] and the mean LOS was 3.736 (HS group) and 4.292 (controls) days (mean difference: - 0.55 days, 95% CI - 0.96 to - 0.15), respectively. The expected costs per patient, when both inpatients and outpatients were included, were €816 ($1111) in the HS inhalation group and €962 ($1310) in the control group. The expected costs per hospitalization, when only inpatients were included, were €2600 ($3540) in the HS inhalation group and €2890 ($3935) in the control group. CONCLUSIONS: HS inhalations slightly reduced the expected hospitalization costs of infant bronchiolitis. However, the low effectiveness, rather than the cost, is the factor that will limit the use of HS inhalations in infant bronchiolitis.
BACKGROUND: This study evaluated the cost-effectiveness of hypertonicsaline (HS) inhalations for infantbronchiolitis, compared to normal saline inhalations or standard treatment without inhalations as controls. METHODS: The decision tree in the decision analysis was used to calculate the expected costs. Actual cost data were obtained from our retrospective case-control study on bronchiolitis treatment. The effectiveness of treatment, based on the hospitalization rate of those admitted to the emergency department and the length of stay (LOS) of those who were hospitalized, was collected from previous studies. For the effectiveness estimations, we made a meta-analysis summarizing the results of the meta-analysis of the Cochrane review in 2013 and the results of 10 studies published after it. RESULTS: The mean hospitalization rate was 24.7% in the HS inhalation group and 32.6% in the control group [risk ratio: 0.80, 95% confidence interval (CI) 0.67-0.96] and the mean LOS was 3.736 (HS group) and 4.292 (controls) days (mean difference: - 0.55 days, 95% CI - 0.96 to - 0.15), respectively. The expected costs per patient, when both inpatients and outpatients were included, were €816 ($1111) in the HS inhalation group and €962 ($1310) in the control group. The expected costs per hospitalization, when only inpatients were included, were €2600 ($3540) in the HS inhalation group and €2890 ($3935) in the control group. CONCLUSIONS:HS inhalations slightly reduced the expected hospitalization costs of infantbronchiolitis. However, the low effectiveness, rather than the cost, is the factor that will limit the use of HS inhalations in infantbronchiolitis.
Authors: Robert G Badgett; Mohinder Vindhyal; Jason T Stirnaman; C Michael Gibson; Rim Halaby Journal: JAMA Pediatr Date: 2015-08 Impact factor: 16.193
Authors: Shawn L Ralston; Allan S Lieberthal; H Cody Meissner; Brian K Alverson; Jill E Baley; Anne M Gadomski; David W Johnson; Michael J Light; Nizar F Maraqa; Eneida A Mendonca; Kieran J Phelan; Joseph J Zorc; Danette Stanko-Lopp; Mark A Brown; Ian Nathanson; Elizabeth Rosenblum; Stephen Sayles; Sinsi Hernandez-Cancio Journal: Pediatrics Date: 2014-11 Impact factor: 7.124
Authors: M Miraglia Del Giudice; F Saitta; S Leonardi; M Capasso; B Niglio; I Chinellato; F Decimo; N Maiello; C Capristo; L Perrone; D Peroni Journal: Int J Immunopathol Pharmacol Date: 2012 Apr-Jun Impact factor: 3.219
Authors: Mark L Everard; Daniel Hind; Kelechi Ugonna; Jennifer Freeman; Mike Bradburn; Cindy L Cooper; Elizabeth Cross; Chin Maguire; Hannah Cantrill; John Alexander; Paul S McNamara Journal: Thorax Date: 2014-12 Impact factor: 9.139